One study with a population of patients with a mix of ER+ and ER-negative cancers failed to show any correlation between response to simvastatin and selected drug- and breast cancer risk-specific biomarkers, serum concentrations of high-sensitivity C-reactive protein, oestrogens, and fasting lipids [28]. Here, ESR1 is linked to breast cancer.